These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22343964)

  • 1. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
    Lorenzana SB; Hughes MD; Grinsztejn B; Collier AC; Luz PM; Freedberg KA; Wood R; Levison JH; Mugyenyi PN; Salata R; Wallis CL; Weinstein MC; Schooley RT; Walensky RP
    AIDS; 2012 Jun; 26(9):1083-93. PubMed ID: 22343964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
    Ouattara EN; Ross EL; Yazdanpanah Y; Wong AY; Robine M; Losina E; Moh R; Walensky RP; Danel C; Paltiel AD; Eholié SP; Freedberg KA; Anglaret X
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):294-302. PubMed ID: 24732870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
    Kimmel AD; Weinstein MC; Anglaret X; Goldie SJ; Losina E; Yazdanpanah Y; Messou E; Cotich KL; Walensky RP; Freedberg KA;
    J Acquir Immune Defic Syndr; 2010 Jul; 54(3):258-68. PubMed ID: 20404739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
    Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
    Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
    Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
    J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.
    Losina E; Touré H; Uhler LM; Anglaret X; Paltiel AD; Balestre E; Walensky RP; Messou E; Weinstein MC; Dabis F; Freedberg KA; ;
    PLoS Med; 2009 Oct; 6(10):e1000173. PubMed ID: 19859538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The survival benefits of antiretroviral therapy in South Africa.
    April MD; Wood R; Berkowitz BK; Paltiel AD; Anglaret X; Losina E; Freedberg KA; Walensky RP
    J Infect Dis; 2014 Feb; 209(4):491-9. PubMed ID: 24307741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.
    Walensky RP; Wood R; Ciaranello AL; Paltiel AD; Lorenzana SB; Anglaret X; Stoler AW; Freedberg KA;
    PLoS Med; 2010 Dec; 7(12):e1000382. PubMed ID: 21209794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.
    Dugdale CM; Phillips TK; Myer L; Hyle EP; Brittain K; Freedberg KA; Cunnama L; Walensky RP; Zerbe A; Weinstein MC; Abrams EJ; Ciaranello AL;
    PLoS One; 2019; 14(11):e0225104. PubMed ID: 31730630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
    Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
    Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.